FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2021/03/031916 [Registered on: 11/03/2021] Trial Registered Prospectively
Last Modified On: 29/01/2022
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   NGA-01 gel for the treatment of Osteoarthritis with joint pain. 
Scientific Title of Study   A double blind, randomized, parallel group study to evaluate efficacy and safety of NGA-01 gel against placebo in the treatment of Osteoarthritis with joint pain. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NUTRIN004 Version 2.0 dated 11 May 2020  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Mukund S Diggikar 
Designation  Principal Consultant 
Affiliation  Ashwin Medical Foundations Moraya Multispeciality Hospital 
Address  Orthopedic Department, Ground Floor, opp PMP Bus Stop, Powerhouse Chowk Chinchwadgaon, Pune

Pune
MAHARASHTRA
411033
India 
Phone    
Fax    
Email  drabhijitmunshi@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Puneet Mittal 
Designation  Clinical Research Consultant 
Affiliation  Mittal Global Clinical Trial Services 
Address  121-B, Mansarovar Industrial Estate Extn Panchli, Baghpat Road

Meerut
UTTAR PRADESH
250005
India 
Phone    
Fax    
Email  puneetmittal@mgcts.org  
 
Details of Contact Person
Public Query
 
Name  Puneet Mittal 
Designation  Clinical Research Consultant 
Affiliation  Mittal Global Clinical Trial Services 
Address  121-B, Mansarovar Industrial Estate Extn Panchli, Baghpat Road


UTTAR PRADESH
250005
India 
Phone    
Fax    
Email  puneetmittal@mgcts.org  
 
Source of Monetary or Material Support  
Galaxa Pharma, Korskildelund 6, 2670 Greve, Denmark 
Nutrin GmbH, Schnaid 36B, 91352 Hallerndorf, Germany 
 
Primary Sponsor  
Name  Nutrin GmbH 
Address  Schnaid 36B, 91352 Hallerndorf, Germany 
Type of Sponsor  Pharmaceutical industry-Global 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Mukund Diggikar  Ashwin Medical Foundations Moraya Multispeciality Hospital  Orthopedic Department, Ground Floor, Opp PMP Bus Stop, Powerhouse Chowk, Chinchwadgaon, Pune 411033
Pune
MAHARASHTRA 
9822371703

drabhijitmunshi@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Moraya Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: M15-M19||Osteoarthritis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NGA-01 gel  1-2 ml twice a day, Topical Application for upto 2 months 
Comparator Agent  Placebo  1-2 ml placebo gel twice a day, Topical Application for upto 2 months 
 
Inclusion Criteria  
Age From  30.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  - Subjects having at least one or more sign and symptoms of Osteoarthritis like Pain in joints (at Knee, Hip, Ankle, Elbow and Shoulder), stiffness, difficulty in flexion and extension, crepitus, swelling etc for more than 3 months prior to the study.
- Pain score of at least 4 cm on a 10-cm linear visual analogue scale.
- Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
- Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.
- Are willing to refrain from using any lotions, gel, balm, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the treatment areas during the treatment period.
- If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study.
- Are able to give written informed consent in a manner approved by the Institutional Ethics Committee and comply with the requirements of the study.
- Are willing to avoid participation in any other interventional clinical trial for the duration of this study. 
 
ExclusionCriteria 
Details  - Are pregnant, breast-feeding, or planning to become pregnant during the study.
- Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gouty Arthritis.
- Complications of OA, like Pseudogout, Spontaneous osteonecrosis of the knee, Ruptured Baker cyst, Bursitis, Anserine bursitis (knee)interfere with the disease and treatment.
- Severe Stomach infection.
- Severely traumatised and/or very severe or mucosal inflammation
- Peritonsillar abscess
- Long term use (≥ 3 times per week within the last month or regular intake within the last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow release analgesic intake including Non Steroidal Anti-Inflammatory Drugs (NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)
- Any anti-inflammatory drugs intake by systemic route within 12 hours before randomization
- Any paracetamol intake within 6 hours before randomisation
- Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6 hours before randomisation
- Heavy smokers (>10 cigarettes/day)
- Have open sores or open lesions in the treatment area(s).
- Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of plaque Arthritis.
- Have participated in any interventional clinical trial in the previous 30 days.
- Have a known sensitivity to any of the constituents of the test product
- Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including oral or parenteral corticosteroids.
- Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.
- Plan to seek alternative treatment of any kind for their Arthritis, in the eligible treatment areas or otherwise, during the trial period. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
Change in pain visual analog scale (VAS) scores (0-10) from baseline  Baseline to Day 60 
 
Secondary Outcome  
Outcome  TimePoints 
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores  Baseline to Day 60 
Change in Numeric Pain Rating Scale (NPRS) score  Baseline to Day 60 
Change in Range of motion (ROM)  Baseline to Day 60 
Change in Assessment score  Baseline to Day 60 
Change in Physician’s Global Assessment of Arthritis  Baseline to Day 60 
Change in Patient’s Global Assessment of Arthritis  Baseline to Day 60 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="60" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   15/03/2021 
Date of Study Completion (India) 20/12/2021 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Osteoarthritis is characterized by the breakdown of cartilage in joints. As cartilage deteriorates, the bones of the joint begin to run against one another, causing stiffness and pain, which often impairs movement. Osteoarthritis also can damage ligaments, menisci, and muscles. Bone or cartilage fragments may float in the joint space, causing irritation and pain. Bone spurs, or osteophytes, may also develop, causing additional pain and potentially damaging surrounding tissues. Around the world, an estimated 10%-15% of adults over 60 have some degree of osteoarthritis. It most commonly affects the joints in the knee, hands, feet, and spine, and is also relatively common in other joints such as the shoulder and hip joints. There are two types of osteoarthritis: primary and secondary. Primary osteoarthritis is a chronic degenerative disease that is related to, but not caused by, aging. As a person ages, the water content of their cartilage decreases, thus weakening it and making it less resilient and more susceptible to degradation. There are strong indications that genetic inheritance is a factor, as up to 60% of all OA cases are thought to result from genetic factors. The main symptoms are pain, loss of ability, and “joint stiffness after exercise or use.” These symptoms are often aggravated by activity or rigorous exercise and relieved during rest, though the disease may eventually progress to the point where the patient even feels pain when resting, and some people report pain so intense that it wakes them up when they are sleeping. Osteoarthritis, at present, cannot be cured, and will likely get worse over time, but the symptoms can be controlled. Treatments vary widely, from alternative medicine, to lifestyle changes such as exercise and diet, to physical aids such as canes or braces, to medications such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids, and more. Osteoarthritis is the most common joint disease of human. Among the elderly knee osteoarthritis is leading cause of chronic disability in developed countries. Some people in India are unable to walk independently from bed and bath-room because of Osteoarthritis of the knee or hip joint. Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety of causes viz. hereditary, developmental, metabolic, and mechanical may initiate processes leading to loss of cartilage. When bone surfaces are not well protected by cartilage, bone may get exposed and damaged. As a result of decreased movement secondary to pain, atrophy of regional muscles, and ligaments may become more lax.
The goal of treatment is to reduce or eliminate the signs and symptoms of Osteoarthritis. Mild to moderate disease is often treated with topical therapies. Sponsor has developed the NGA-01Gel containing the fixed dose combination of alcohol and water mixture, with active herbal ingredients, without preservatives and dyes. The Gel is easy to apply, and the cosmetic appearance is that of a white, milky gel, easily-spreadable that absorbs completely into the skin a few minutes after application and it is expected that the Gel will differentiate from marketed formulations by patient preference for the gel and gel.
 
Close